FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 33 filers reported holding FUSION PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,153,627 | -44.3% | 2,751,395 | 0.0% | 0.24% | -35.8% |
| Q2 2023 | $12,849,014 | +23.5% | 2,751,395 | -0.3% | 0.37% | +21.2% |
| Q1 2023 | $10,404,959 | +297.0% | 2,759,936 | +162.2% | 0.31% | +274.4% |
| Q2 2022 | $2,621,000 | -72.5% | 1,052,445 | -14.2% | 0.08% | -57.1% |
| Q1 2022 | $9,534,000 | -6.8% | 1,227,017 | -50.0% | 0.19% | +141.8% |
| Q4 2021 | $10,234,000 | +3.0% | 2,454,034 | +95.6% | 0.08% | -45.1% |
| Q3 2021 | $9,936,000 | -65.4% | 1,254,607 | -64.7% | 0.14% | -22.6% |
| Q2 2021 | $28,686,000 | +37.2% | 3,550,334 | +82.1% | 0.19% | -29.5% |
| Q1 2021 | $20,905,000 | -20.4% | 1,950,167 | -12.8% | 0.26% | -6.4% |
| Q4 2020 | $26,273,000 | -2.2% | 2,235,983 | 0.0% | 0.28% | -28.1% |
| Q3 2020 | $26,877,000 | -25.2% | 2,235,983 | 0.0% | 0.39% | -32.8% |
| Q2 2020 | $35,955,000 | – | 2,235,983 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,140,000 | 2.34% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $3,887,000 | 1.96% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,340,000 | 1.91% |
| Sio Capital Management, LLC | 260,448 | $649,000 | 0.24% |
| Orbimed Advisors | 3,224,770 | $8,030,000 | 0.15% |
| Artal Group S.A. | 750,000 | $1,868,000 | 0.10% |
| TPG GP A, LLC | 2,551,794 | $6,354,000 | 0.10% |
| Perceptive Advisors | 1,052,445 | $2,621,000 | 0.08% |
| Rock Springs Capital Management LP | 809,854 | $2,017,000 | 0.06% |
| FEDERATED HERMES, INC. | 3,124,100 | $7,779,000 | 0.02% |